medical devices

Three healthcare stocks—Pfizer (6.5% yield), Medtronic (3.6% yield with 48-year dividend streak), and Omega Healthcare (5.8% yield)—offer retirees attractive income streams amid aging demographics.

Medtronic offers a more attractive valuation (22x P/E vs. 55x) than Intuitive Surgical, with 3.6% dividend yield and Hugo robot growth potential.

$BDX trades at significant discount despite 60% infusion pump dominance, 90%+ recurring revenue, and $4B capital deployment driving billion-dollar growth platforms.

Embecta plummeted 57.8% after missing earnings and revenue targets in fiscal Q2 2026, with management sharply reducing full-year guidance.

DexCom beats Q1 earnings with $1.2B revenue, boasts 20 Buy ratings. New products and margin expansion drive 40% upside potential.

Three dividend stocks—AbbVie (3.3%), Medtronic (3.6%), and Enbridge (5.2%)—create monthly income through staggered payments. Combined strategy offers consistent cash flow from financially strong healthcare and energy companies.

Intuitive Surgical's decade-long 580% rally stems from recurring revenue—75% of total—from instruments and services, not robot sales alone.

Global sleep apnea devices market expected to grow 7.05% annually through 2034, driven by rising prevalence and technological advances in CPAP and BiPAP devices.

Abbott reports strong clinical trial data for AFib and cardiac devices, with 87% arrhythmia-free rates and 98.3% safety in FlexPulse study, supporting future revenue growth.

Edwards Lifesciences beats Q1 earnings expectations, reporting 78-cent EPS and $1.65B revenue while raising 2026 guidance on strong heart valve device growth.

Global perfusion systems market projected to grow 5% annually from USD 1.5B (2025) to USD 2.4B (2034), driven by cardiovascular disease prevalence and transplant procedures.

Intuitive Surgical's recent selloff creates a buying opportunity with 30%+ upside potential, supported by strong Q1 growth, market dominance, and aggressive buybacks.

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.

Global respiratory care devices market projected to grow 8% annually to $47.5B by 2034, driven by chronic disease prevalence and home healthcare demand.

Royal Philips secured FDA 510(k) clearance for its Rembra platform, enabling faster CT imaging and radiation therapy planning with capacity for 270 daily exams.

Teleflex shares jump 8% after CVC Capital Partners and GTCR jointly bid to take the medical device maker private, following activist pressure.

Global laparoscopy devices market projected to reach USD 23.5B by 2034 from USD 11.1B in 2025, growing at 9% CAGR amid rising minimally invasive surgery demand.

Global surgical drill bits market to grow from $316M in 2025 to $540M by 2035 at 5.5% CAGR, driven by infrastructure development and rising surgical volumes.

Abbott offers diversified healthcare exposure with dividend income; Dexcom provides pure CGM growth but faces GLP-1 drug competition and concentration risk.

Global foot and ankle devices market projected to surge from $5.9B in 2025 to $9.2B by 2034, driven by aging populations and diabetes complications.